$1 million grant supports manufacturing of COVID-19 treatments and vaccines

Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19.

The funding will support new equipment and infrastructure at The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), which has been successfully manufacturing therapies using cells, genes and viruses for clinical trials in Canada and abroad for more than 10 years.

The research team includes: Dr. Duncan Stewart, Executive Vice-President of Research at The Ottawa Hospital and a professor at the Department of Cellular and Molecular Medicine; Dr. John Bell, professor in the Department of Biochemistry, Microbiology and Immunology; Dr. Carolina Ilkow, assistant professor in the Department of Biochemistry, Microbiology and Immunology; Dr. David Courtman, assistant professor of cardiology in the Department of Medicine, and Dr. Bernard Thébaud, professor in the Department of Cellular and Molecular Medicine. 

The funding will enhance the BMC’s ability to support projects related to COVID-19, including:

“Our Biotherapeutics Manufacturing Centre has already played a crucial role in launching more than 15 world-first clinical trials,” said Dr.Stewart. “Today’s funding will now allow us to harness this success to help in the global fight against COVID-19.”

The funding was announced by the Canada Foundation for Innovation, as part of a national announcement of more than $28 million for infrastructure related to COVID-19 research


dr John Bell

Dr. John Bell (pictured here) and Dr. Carolina Ilkow (top photo) are turning their expertise in making oncolytic viruses to develop a vaccine against COVID-19.

Bernard Thebaud looks into a microscope

Dr. Bernard Thébaud's lab studies the mechanisms of lung development, injury and repair.


Back to top